SIGN-R1 also binds to zymosan, to the capsular polysaccharide of S. pneumoniae, and with low affinity to dextran and is Abiraterone manufacturer highly expressed by macrophages [101, 103–105]. Bovine serum antigen (BSA) consisting, 51 mannoside residues (Man(51)-BSA) binds to SIGN-R1 on lamina propria DCs in the gastrointestinal tract and induces IL-10 cytokine secretion by DCs, but not IL-6 and IL-12p70 [106]. In vitro and in vivo, Man(51)-BSA stimulates CD4+ type 1 regulatory T-like cells (Tr-1) but not CD4+CD25+Foxp3+ Inhibitors,research,lifescience,medical regulatory T cells, suggesting that SIGN-R1 induces tolerance to antigens [106]. LSECtin. LSECtin (liver and lymph node sinusoidal endothelial cell C-type lectin, Clec4G) is

a type-II transmembrane C-type Inhibitors,research,lifescience,medical lectin protein, similar to the related proteins DC-SIGN and L-SIGN and is expressed in liver, lymph node cells, and sinusoidal endothelial cells but

not monocyte derived DCs (Table 1). LSECtin binds to N-acetyl-glucosamine and fucose but does not bind to galactose and may function in vivo as a lectin receptor [107]. LSECtin is coexpressed Inhibitors,research,lifescience,medical with DC-SIGNR and CD23 and binds to ebola virus, filovirus glycoproteins, lymphocytic choriomeningitis virus, and, to the S-protein of SARS coronavirus but does not interact with HIV-1 and hepatitis C [108]; although a study suggested that LSECtin binds to hepatitis C virus, the interaction was in association DC-SIGNR with [109]. Ligands binding to LSECtin are not inhibited Inhibitors,research,lifescience,medical by mannan but by EDTA suggesting that the LSECtin does not bind to mannose [108]. Recently, LSECtin was shown to bind with CD44 [110]. Another study, regarding the expression of LSECtin demonstrated LSECtin, to be expressed on human peripheral

blood, thymic DCs, monocyte-derived macrophages and DCs [111], and to human Kupffer cells [112]. Antibody or ligand-mediated engagement of LSECtin activates rapid internalization Inhibitors,research,lifescience,medical of LSECtin [111] indicating that LSECtin may be a suitable receptor for targeting antigens in the development of vaccination regimes. Further Anacetrapib work is required to determine the viability of LSECtin to be an appropriate target for immunotherapy studies. CIRE. CIRE (C-type lectin immune receptor, CD209) is a selleck chemicals Volasertib murine type 2 membrane protein which belongs to the C-type lectin receptors and is preferentially expressed by immature CD8− splenic DCs (CD8−CD4+ and CD8−CD4−), on some CD4+ DCs, and on plasmacytoid pre-DCs, with no expression on CD8+ DCs, macrophages, or monocytes (Table 1 and Figure 1) [113]. CIRE that has 57% identity with DC-SIGN is the murine homolog to human DC-SIGN and both bind mannose residues [114]. However, CIRE is downregulated after activation, and incubation with cytokines IL-4 and iL-13 does not enhance expression of CIRE, even though DC-SIGN is enhanced, suggesting differences in gene regulation between the two receptors [113].